Top news of the week: 22.06.2022.
AstraZeneca Rumored to Have Set Sights on Mereo BioPharma Buyout
AstraZeneca appears to have taken an interest in Mereo BioPharma and is considering a buyout, according to circulating speculations.
Bavarian Nordic Takes on Pfizer-BioNTech with COVID-19 Booster Candidate
Bavarian Nordic announced that the upcoming Phase III trial for its COVID-19 booster candidate has been redesigned to compete against licensed mRNA-based vaccines.
Merck, Emergent, Affinivax and Ocugen Level Up in Vaccine Development
The week started with positive updates in the vaccine development space against various infectious diseases from Emergent, Merck, Affinivax, and Ocugen.
Disappointing Results End 9 Meters' Phase III Trial for Celiac Treatment
9 Meters Biopharma is discontinuing a Phase III clinical trial for larazotide, a treatment for celiac disease as interim results were not statistically significant.
Is Merck planning a $30bn-plus move for Seagen?
Rumour mill says Merck is interested in buying Seagen, but may be dissuaded by possible antitrust opposition that has pegged back other biotech M&A activity
Strong dealmaking dominated by Sanofi, BMS
While Pfizer Inc. remains active with mergers and acquisitions, Sanofi SA and Bristol Myers Squibb Co. are major players in the top six biopharma deals of 2022. So far this year, the ...
Rumour mill says AstraZeneca may be eyeing a takeover of Mereo
Report suggests AstraZeneca is considering a takeover of UK biotech Mereo BioPharma, though its hard to see a compelling driver for such a deal
3D Printed System Developed for Harvesting Stem Cells from Bioreactors
The new 3D printed system was designed to process mesenchymal stem cells, a type of adult stem cell that can divide and differentiate into multiple tissue cells including bone, cartilage, ...